INS and diabetes mellitus: Adding another agent, like GLPRA may also improve treatment burden through the reduction in the insulin requirements, therefore potentially improve patient-centered outcomes, but that remains to be studied.37,38 Altogether, it is important to avoid clinical inertia in the treatment of diabetes in kidney transplant recipients.